about
DUX4c is up-regulated in FSHD. It induces the MYF5 protein and human myoblast proliferationA new peptidic vector for molecular imaging of apoptosis, identified by phage display technology.DUX4, a candidate gene for facioscapulohumeral muscular dystrophy, causes p53-dependent myopathy in vivoThe FSHD atrophic myotube phenotype is caused by DUX4 expression.FSHD myotubes with different phenotypes exhibit distinct proteomes.DUX4 differentially regulates transcriptomes of human rhabdomyosarcoma and mouse C2C12 cellsAntisense Oligonucleotides Used to Target the DUX4 mRNA as Therapeutic Approaches in FaciosScapuloHumeral Muscular Dystrophy (FSHD).Facioscapulohumeral muscular dystrophy (FSHD): an enigma unravelled?Helicase-like transcription factor exhibits increased expression and altered intracellular distribution during tumor progression in hypopharyngeal and laryngeal squamous cell carcinomas.The helicase-like transcription factor is a strong predictor of recurrence in hypopharyngeal but not in laryngeal squamous cell carcinomas.DUX4c, an FSHD candidate gene, interferes with myogenic regulators and abolishes myoblast differentiation.Intracellular trafficking and dynamics of double homeodomain proteins.An isogenetic myoblast expression screen identifies DUX4-mediated FSHD-associated molecular pathologies.On-chip microelectrophoresis for the study of in vitro nonhomologous end-joining DNA double-strand break repair.Functional muscle impairment in facioscapulohumeral muscular dystrophy is correlated with oxidative stress and mitochondrial dysfunction.Measurement of translesion synthesis by fluorescent capillary electrophoresis: 7,8-dihydro-8-oxodeoxyguanosine bypass modulation by natural products.Expression of the helicase-like transcription factor and its variants during carcinogenesis of the uterine cervix: implications for tumour progression.
P50
Q21091176-502B22B2-36F3-4C98-9194-1E4988D70501Q33246075-6A451092-B8E6-49C4-873C-5183E14BCB9EQ33903001-221A7BDF-D545-47C1-9E3F-838A61605BFAQ34067055-3AC2EE04-8F98-4DDB-AD70-D9C83AC2ADBAQ34525765-FF8030FC-7206-4808-902C-74E2A1D1B93FQ34746238-956BF363-7F3A-47F7-B771-1FC43DEEB589Q37724109-68D5DB78-F7FF-4831-9EE6-29E97B3FAA68Q37943770-278021DA-C026-4A45-9C23-8B64502A52D3Q38475633-9F64B651-4DAF-45DD-9837-43C7AA7981F8Q39824029-0B895C9E-C2D3-40C1-9664-96DD9F66CEA9Q39947850-6CE84729-D296-4B36-BD13-7CBBFDAA2F3FQ40458725-BFA21E44-E52B-476C-8DB3-DD86A97DF24AQ42143520-5ED21758-7C23-481B-808D-B09EC5800437Q43672601-E90711CE-AEB8-4B1A-92A7-4E58A6D03530Q45335566-4DA7C13F-93E0-480E-A481-51DA8F7E3F5FQ50957235-FA24BA12-A662-489A-9BC7-9C8F6238A695Q53286824-29CA29E7-8BC5-41B5-9D53-D50F16E2E187
P50
description
hulumtuese
@sq
onderzoeker
@nl
researcher
@en
ricercatrice
@it
հետազոտող
@hy
name
Alexandra Belayew
@ast
Alexandra Belayew
@en
Alexandra Belayew
@es
type
label
Alexandra Belayew
@ast
Alexandra Belayew
@en
Alexandra Belayew
@es
prefLabel
Alexandra Belayew
@ast
Alexandra Belayew
@en
Alexandra Belayew
@es
P214
P106
P21
P214
P31
P496
0000-0001-5115-2424
P735
P7859
viaf-313542465